Abstract Inflammation is closely intertwined with pathogenesis of Parkinson's disease (PD). Increasing evidence suggests that inhibition of glia-mediated inflammation might represent a promising therapeutic target for PD. Glia maturation factor (GMF), an inflammatory protein, predominantly localized in astrocytes is previously isolated, sequenced and cloned in our laboratory. In the present investigation, we demonstrate that GMF-deficiency in astrocytes upregulates the antioxidant status and limit the extent of lipid peroxidation and production of reactive oxygen species (ROS) along with diminished nuclear factor-κB-mediated inflammatory responses in 1-methyl-4-phenylpyridinium (MPP + )-induced toxicity. Primary astrocytes obtained from wild-type (Wt) and GMF-deficient (GMF-KO) mice were treated with 5, 10, and 20 μM MPP + for 24, 48, and 72 h in vitro. Our results show decreased release of ROS and increased level of glutathione in astrocytes obtained from GMF-KO mice when compared to astrocytes derived from Wt mice following MPP + treatment. Additionally, we found decreased activity of NF-κB, and reduced levels of proinflammatory tumor necrosis factor-α, interleukin-1β (IL-1β), IL-17, IL-33, and chemokine (C-C motif) ligand 2 (CCL2) in GMF-KO astrocytes when compared to Wt astrocytes. Our overall results suggest that GMF-KO astrocytes are significantly resistant to MPP + toxicity when compared to Wt astrocytes.
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Interleukin-1 iNOS Inducible nitric oxide synthase LDH Lactate dehydrogenase MPP 1-Methyl-4-phenyl-pyridine MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide NF-kB Nuclear transcription factor-κB PD Parkinson's disease ROS Reactive oxygen species SDS Sodium dodecyl sulfate TBARS Thiobarbituric acid reactive substance TNF-α Tumor necrosis factor-alpha Wt Wild-type tetrahydropyridine (MPTP) are known to be associated with the pathogenesis of PD in human and in animal models of PD. Several studies have suggested involvement of glia activation in the pathogenesis of PD along with other components of neurodegenerative processes, such as oxidative stress, inflammation, and apoptosis. Human postmortem studies have also suggested that altered glial functions and oxidative damage to lipids, proteins, and DNA in the PD brains (Dexter et al. 1994) . Astrocytes are abundant neuron-supporting glial cells that equipped with powerful arsenal of antioxidative molecules and neurotrophic factors. Astrocytes most likely improve dopaminergic neuronal survival by uptake of toxic molecules, such as glutamate and α-synuclein (Hazell et al. 1997; Lee et al. 2010; Miyazaki et al. 2013) . Numerous studies have demonstrated that astrocytes play an important role in neurodegenerative disorders and exert a protective function against oxidative stress because of their effects on the metabolism of the antioxidant glutathione (GSH) and the defense against reactive oxygen species (ROS) (Wilson, 1997) . Indeed, astrocyte-derived antioxidants reduce oxidative stress level in the surrounding neurons (Makar et al. 1994; Chen et al. 2009 ). Recently, it has been reported that astrocytes expressed metallothionein, protecting dopaminergic neurons through their quinone-quenching or free radical-scavenging properties (Miyazaki et al., 2011) . Thus, increased numbers of healthy astrocytes, which possess antioxidative potential, are potentially viable therapeutic approach to prevent the degenerative process of PD. The neurotoxin 1-methyl-4-phenylpyridinium (MPP + ), a high-affinity inhibitor of mitochondrial complex I, is a metabolite of MPTP oxidation formed by monoamine oxidase-B in astrocytes and it is a common neurotoxin used to investigate the alteration of astrocytic functions relevant to PD.
Glia maturation factor (GMF), a highly conserved brain protein, was previously isolated, sequenced and cloned in our laboratory (Lim et al. 1990; Kaplan et al. 1991; Zaheer et al. 1993) . It has been previously documented that GMF is an intracellular regulator of stress-activated signal transduction and activates p38 MAP kinase and transcription factor NF-κB in astrocytes Zaheer and Lim 1996; Lim et al. 2000; Zaheer et al. 2001) . We have also shown that the overexpression of GMF in astrocytes leads to the destruction of primary oligodendrocytes, the myelin-forming cells in the CNS, by interactions between astrocytes, microglia, and oligodendrocytes (Zaheer et al., 2007a) . In addition, GMF has an apparently high rate of oxidase activity causing the formation of ROS, which can initiate lipid peroxidation and damage cell membranes (Kaimori et al. 2003; Zaheer et al. 2004) . Recently, we have demonstrated involvement of proinflammatory GMF in the pathogenesis of several neurodegenerative diseases (Zaheer et al. 2007b; . However, the role of GMF in MPP + -induced toxicity in astrocytes was not investigated. Ever since, deficiency of GMF modulates oxidative stress and inflammation in number of pathological conditions (Zaheer et al. 2007b; , and is also crucial for the survival of dopaminergic neurons in the pathogenesis of PD (unpublished results). Therefore, in the present investigation, we report that GMF-deficient astrocytes are more resistant to MPP + -induced toxicity than astrocytes from Wt mice and this resistance may be associated with limitation of oxidative threat and down regulation of NF-κB-mediated inflammation.
Materials and Methods
Reagents
Enzyme-linked immunosorbent assay (ELISA) kits for tumor necrosis factor-alpha (TNF-α), chemokine (C-C motif) ligand 2 (CCL2), interleukin-17 (IL-17) and IL-33 and IL-1 β were purchased from R&D Systems (Minneapolis, MN). Assay kits for ROS and NF-κB were purchased from Abcam (Cambridge, MA). Assay kits for GSH and thiobarbituric acid reactive substance (TBARS) were from Cayman Chemical Company (Ann Arbor, MI). Antibody for iNOS was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). MPP + iodide was purchased from Sigma-Aldrich (St. Louis, MO). Pregnant C57BL/6 mice were from Charles River (Wilmington, MA). GMF-deficient (GMF-KO) mice were maintained by backcross breeding to C57BL/6 for 10-12 generations. These mice were bred and maintained in the animal colony at The University of Iowa according to the guidelines of Institutional Animal Care and Use Committee (IACUC).
Primary Cultures of Mouse astrocyte
Primary cultures of astrocytes were prepared essentially as described previously by us (Zaheer et al. 2001 ) and by others (Assouline et al. 1983; Delgado and Ganea 2003) . In brief, mixed glial culture were established from newborn mouse brain by trypsin dissociation and cultured for 8-10 days as previously described. Astrocytes were purified by differential attachment as follows. The mixed glial cells were subcultured by trypsinization and reseeding. Twenty minutes after plating, when approximately two thirds of the cells (mainly astrocytes) have attached, the medium was changed to remove the floating unattached cells. The adhered cells were permitted to grow to a confluent monolayer. Cells were subcultured at least twice to achieve homogeneous monolayers of astrocytes. Astrocytes were grown in DMEM/F12 (Life Technologies, Grand Island, NY) containing 5 % fetal bovine serum. Astrocyte cultures were >98 % positive for glial fibrillary acidic, a specific marker for astrocytes. 6 cells /ml in complete medium for overnight at 37°C. Then, the cells were incubated with various concentrations of MPP + (5, 10, and 20 μM) for 24, 48, and 72 h in serum free medium. After the termination of incubation, cells were collected for the assays of TBARS, GSH, ROS, and the culture supernatant were collected for estimation of proinflammatory cytokines and chemokine. Protein was assayed in culture supernatant by BCA method.
Cytotoxicity Assay
Viability of astrocytes was quantitated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay (Hansen et al. 1989) . In order to investigate the influence of MPP + on cell viability, we treated GMF-KO astrocytes and Wt astrocytes with MPP+ at different concentrations (5-100 μM). Ten microliters of MTT solution (5 mg/ml) were added to each well and incubated for 4 h at 37°C. The blue formazine formed in viable cells was dissolved by adding an equal volume of lysis buffer made of 20 % SDS dissolved in a 1:1 mixture of water and N,N-dimethyl-formamide, pH 4.7. The optical density was measured with a plate reader at 595 nm. Cell death was assessed in 50 μl cell supernatant by using a commercially available kit (CytoTox 96 nonradioactive cytotoxicity assay kit, Promega, WI, USA) according to the manufacturer's instructions. The amount of lactate dehydrogenase (LDH) release into the culture medium upon cell lysis was measured by the conversion of a tetrazolium salt into red formazan product. The absorbance, proportional to the lysed cells, was measured at 490 nm. The amount of LDH released by the cells in the presence of 1 % Triton X-100 was considered maximal absorbance.
Lipid Peroxidation, and Glutathione and Nitric Oxide Assays TBARS, as a marker of lipid peroxidation, and GSH and nitric oxide (NO) were detected according to the kit manufacturer's instructions. The TBARS results were expressed as nanomoles TBARS formed per hour per milligram protein. GSH was calculated in terms micromoles GSH formed per milligram protein using a molar extinction coefficient of 13.
. The NO results were expressed as micromoles NO release per milligram protein.
Measurement of ROS Generation
ROS formation was detected by a commercially available kit according to the manufacturer's instruction using a compound, DCFDA. In brief, after cell sonication in a lysis buffer (0.1 % SDS, Tris-HCl, pH 7.4) at 4°C, samples were centrifuged at 6,000g for 20 min at 4°C. Supernatants were collected and subjected to fluorescence analysis at 485 nm excitation and 535 nm emissions using a microplate reader.
NF-κB Assay NF-κB activity was determined by mouse phospho-Rel A/NF-κB p65 immunoassay kit (Abcam, Cambridge, MA) according to the manufacturer's instruction. Briefly, cells were seeded in 96-well plate and incubated with 20 μM concentration of MPP for 24, 48, and 72 h at 37°C. After preincubation in blocking buffer, cells were incubated overnight with primary antibody at 4°C followed by appropriate secondary antibody. Cells were then exposed to substrate solution for 20-40 min and read the plate using a fluorescence plate reader.
Immunoblotting
Western blot was performed to detect iNOS in the cell fraction as described previously . After exposure to MPP + , cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1 % NP-40, 0.5 % deoxycholate) containing protease (Roche Diagnostics, Indianapolis, IN) and phosphatase inhibitor cocktails (Cell Signaling Technology, Danvers, MA). Samples containing equal amounts of protein (35 μg) were separated in 10 % SDS-polyacrylamide gels. Proteins were transferred onto PVDF membrane and incubated overnight at 4°C with primary rabbit polyclonal antibody against NOS2 (Santa Cruz, CA; 1:200 dilutions) followed by secondary antibody conjugated to horseradish peroxidase (HRP). Proteins recognized by the antibody were visualized by enhanced chemiluminescence Femto kit (Thermo Scientific, Rockford, IL). Blots were stripped and reprobed for β-actin (Sigma) as a loading control. Bands intensity was measured by densitometry and quantified using NIH-Image J software.
Cytokines and Chemokine Assay by ELISA TNF-α, IL-1β, IL-17, IL-33, and CCL2 protein concentrations in the culture supernatants were estimated by ELISA as specified in the manufacturer's protocol. The lower detection limits of these ELISA are in the range of 8-12 pg/ml.
Statistical Analysis
Results are expressed as mean±SEM. Statistical analysis of the data was done by independent student t test. The p value less than 0.05 were considered statistically significant.
Results
GMF Deficiency Protects Astrocytes from MPP + -Induced Toxicity
The primary cultures of astrocytes from GMF-KO mice and GMF-containing Wt mice were incubated with variable concentrations (0-100 μM) of MPP + and the cell viability was measured by MTT assays. MPP + at 24 (Fig. 1a ) and 48 h (Fig. 1b) caused a concentration-dependent decrease of viable astrocytes derived from Wt mice. In contrast, cell viability was higher in GMF-KO astrocytes when compared with Wt astrocytes following MPP + treatment. The amount of LDH release into the culture medium upon cell lysis was measured by the conversion of a tetrazolium salt into red formazan product as described in Experimental Procedures. Results in Fig. 1c (Fig. 2b) . Similarly, we found significant Fig. 1 (Fig. 2c) .
GMF-Dependent Downregulation of NF-κB Activity in Astrocytes Following MPP + Treatment
It is known that NF-κB regulates the expression of iNOS and several proinflammatory cytokines and chemokines. ELISA results (Fig. 3) Fig. 3 .
Western blot analysis was performed to determine the expression of iNOS in GMF-KO astrocytes and Wt astrocytes following MPP + treatment (20 μM). Expression of iNOS was significantly (p<0.05) decreased in GMF-KO astrocytes when compared to Wt astrocytes following MPP + toxicity (Fig. 4) . Total NO level was significantly decreased in GMF-KO astrocytes when compared to Wt astrocytes following MPP + toxicity in dose and time-dependent fashion (Fig. 5) (Fig. 6) . Similarly, we found the significant (p<0.05) decrease in proinflammatory cytokines and chemokine in the GMF-KO astrocytes as compared to Wt astrocytes following MPP + toxicity at 48 and 72 h in a dose-dependent manner (Fig. 6) . These results indicate that MPP + -induced release of proinflammatory cytokines and chemokine were significantly diminished in GMF-KO astrocytes.
Discussion
Enhanced expression of GMF in the brain has been documented in many conditions associated with inflammation and neurodegeneration (Zaheer et al., 2007a; Zaheer et al., 2007b; Thangavel et al., 2012) . Numerous studies have shown that inflammation is common to a variety of neurodegenerative diseases, including Parkinson's disease. Chronic inflammation usually involves activation of glial cells resulting in the production of inflammatory mediators such as cytokines/ chemokines, ROS and RNS. In this regard, our novel approach to down regulate GMF expression in CNS to stop the deleterious inflammation associated with neurodegeneration is novel because such an approach may be beneficial in Parkinson's disease. We have recently demonstrated, using GMF-deficient (GMF-KO) mice that an absence of endogenous GMF delayed the onset and drastically reduced loss of dopaminergic neurons in substantia nigra and striatum of mice following MPTP administration (unpublished results). In this study, we report that GMF-KO astrocytes showed limited oxidative damage and secretion of inflammatory mediators following MPP + treatment, demonstrating neuroinflammatory function of GMF in MPP + toxicity. Our present results show decreased release of ROS and increased level of GSH in GMF-KO astrocytes when compared to Wt astrocytes following MPP + treatment. We also found decreased activity of NF-κB, and expression of reduced levels of proinflammatory TNF-α, IL-1β, IL-17, IL-33, and CCL2 in GMF-KO astrocytes compared to Wt astrocytes following MPP + treatment. Our results suggests that GMF-KO astrocytes are more resistant to PD relevant MPP + toxicity compared to Wt astrocytes by reducing oxidative loads along with diminished levels of NF-κB and proinflammatory molecules. Our previous studies have demonstrated that enhanced expression of GMF in glia aggravates inflammation (Zaheer et al. 2002; .
Inflammation mediated by the activation of astrocytes plays a crucial role in the neurodegeneration disorders such as PD. Activated astrocytes release a numerous proinflammatory cytokines, including TNF-α and chemokines such as Nitric oxide (NO) levels were significantly decreased in GMF-KO astrocytes following MPP + treatment in a dose-(5, 10, and 20 μM) and time-dependent (24, 48, and 72 h) manner. Astrocytes were incubated with MPP + for 24, 48, and 72 h and then the culture media were collected for NO assay using commercial kit. Values are expressed as means±SEM (n=5). *p<0.05, compared with the Wt astrocytes and GMF-KO astrocytes treated with MPP CCL2, as well as ROS and NO (Regan et al. 2001; Matos et al. 2008) . These factors may contribute to the neuroinflammatory process, resulting in dopaminergic neuronal cell death in PD. In the present study, we investigated whether deficiency of GMF confers modulatory effects on MPP + -induced toxicity in the mouse astrocytes in vitro. We demonstrate that GMF-KO astrocytes showed decreased release of a variety of proinflammatory mediators such as TNF-α and IL-1β through the suppression of NF-κB and its responsive gene, which suggests that deficiency of GMF could effectively ameliorate MPP + -induced toxicity. Previous studies have indicated that GMF deficiency contended the oxidative loads and limits the inflammatory response via the downregulation of NF-κB and its responsive genes. Our present study with LDH and MTT assays indicate that GMF-KO protects mouse astrocytes from MPP + -induced toxicity. Oxidative stress has been proposed as one major factor leading to cell death. ROS, NO production, and lipid peroxidation may initiate neurotoxic cascade of events. Thus, the excess of free radicals may lead to peroxidative impairment of membrane lipids and consequently disrupt neuronal functions and cause cellular death. GSH is the major antioxidant present in high amounts in astrocytes as compared with neuronal cells and free radicals. It eliminates H 2 O 2 and organic peroxides by GPx. A reduction in the level of GSH may impair H 2 O 2 clearance and promote formation of OH•, the most toxic molecule to the brain, leading to more oxidant load and further oxidative damage (Dringen 2000; Khan et al. 2013) . In the present study, MPP + treatment with different concentrations at three different time points to astrocytes caused an overproduction of free radicals which, in turn, caused oxidative damages to membrane lipid and protein levels, and ultimately led to a decrease in GSH content. Our results suggest that GMF could protect astrocytes from oxidative stress generated by MPP + which is consistent with previous reports where MPP + -induced toxicity leads to oxidative damage (Sundar Boyalla et al. 2011; Xiao et al. 2011) .
Glial activation is considered a rapid cellular response to inflammation (McNaught and Jenner 1999; Koprich et al. 2008) . Activation of astrocytes induces cytotoxic mediators such as NO and inflammatory cytokines, which may contribute to the disease progression including PD. Regulation of NF-κB is known to be redox-sensitive which depends on the availability of ROS. Several in vivo studies have reported the activation of NF-kB in response to MPP + toxicity (Liu et al. 2010; Song et al. 2012 ). The present findings are in agreement with our earlier studies where overexpression of GMF led to NF-kB activation and small interfering RNA-mediated GMF knockdown almost completely blocked the GMF-dependent NF-kB activation (Lim et al. 2000; Zaheer et al. 2007a) . NO production resulting from induced NOS2 gene expression and subsequent iNOS enzyme activation is a primary contributor to the inflammatory response. High expression of inflammatory cytokines are implicated in PD, with the observation of -induced toxicity. These cytokines may have deleterious effects on the dopaminergic neurons in PD. Cytokines also directly bind to their receptors on the cell surfaces on dopaminergic neurons to initiate the process of neurodegeneration. Once activated, these cytokine receptors could trigger intracellular death related signaling pathways. In turn, this sequence of events results in an increased proinflammatory cytokine production, enhancement of leukocyte infiltration, and upregulation of adhesion molecules that contribute to both necrotic and apoptotic cell death (del Zoppo et al. 2000; Tansey and Goldberg 2010) . Increased expression of proinflammatory cytokines and chemokines occurs in the CNS diseases such as Alzheimer's disease, Multiple Sclerosis, and PD. CCL2 facilitates the entry of inflammatory cells that are important for the CNS tissue damage and demyelination in the neurodegenerative diseases. Our present study showed that MPP + -induced CCL2 release from astrocytes, which could attract glial cells and inflammatory infiltrates at the site of inflammation in PD brain. Since the release of CCL2 is reduced in the GMF-KO mice, GMF-KO strategy may reduce the neuroinflammatory processes by decreased accumulation of inflammatory infiltrates. Recently, IL-17 secreting Th17 cells have been shown to infiltrate the mouse brain following neurodegeneration (Reynolds et al. 2010; Browne et al. 2013) . Although IL-17 plays an important role in disease pathogenesis in autoimmune diseases ), Alzheimer's disease (Nie et al. 2013; Zhang et al. 2013) , PD and post stroke neurodegeneration (Swardfager et al. 2013) , its role in PD is not yet clear. Astrocytes, microglia, and neurons express receptor for IL-17, activation of which is known to activate NF-kB and GSK3 (Zepp et al. 2011 ). Moreover, IL-17 is known to induce activation of microglia (Murphy et al. 2010) , and neuronal injury (Wang et al. 2009 ). Recently, Reynolds et al. have reported the upregulation of IL-17 concentration in the mouse brain following MPTP treatments (Reynolds et al. 2010) . In agreement with this study, we also found upregulated release of IL-17 in mouse primary astrocytes and deficiency of GMF decreases its release significantly.
IL-33 has been shown to be increased in the tissues of various inflammatory and autoimmune diseases (Li et al. 2012; Pei et al. 2014) . Recently, we have shown an increase of IL-33 release by recombinant GMF from mouse astrocytes and that IL-33 induces neuronal degeneration through the release of proinflammatory molecules such as NO and TNF-α ). Our present study indicates that MPP + also increased the release of IL-33 as well as NO from the astrocytes, may play an important role in MPP + -induced neuronal degeneration and that this effect was reduced in GMF-KO astrocytes indicating the GMF deficiency may lead to neuroprotection. Additionally, MPP + increased the release of TNF-α and IL-1β, the cytokines that are already known to induce neurodegeneration (Marx et al. 2001) . Thus, GMF deficiency is associated with concomitant reduction of the associated oxidative loads, NF-kB downregulation, reduced iNOS expression, and cytokine levels after MPP + toxicity. The inhibition of NF-kB translocation, iNOS expression, and cytokine level show that GMF has an inflammatory activity and deficiency of GMF could ameliorate the MPP + -induced toxicity. It could also be useful in slowing neuronal death and therefore, halting progression of the disease.
It has been already established that GMF is an important regulator of CNS inflammation (Lim et al. 2000; Zaheer et al. 2008; and inhibition of endogenous GMF by targeting GMF will provide an avenue for effective and selective strategy to slow deleterious oxidative and inflammatory processes in PD.
Using GMF-KO astrocytes, we determined how the lack of GMF affects the oxidative status following MPP + insult. By studying side-by-side signal transudations in the total absence of endogenous GMF and in the presence of GMF, a stark contrast was obtained that facilitated to delineate the function of GMF inside the cell. These results suggest that deficiency of GMF might delay the onset and slow the progression of MPP + -induced toxicity in astrocytes by resistant to oxidative threats and downregulation of NF-kB mediated inflammatory responses. Further in-depth mechanistic study is needed to clarify the protective effect against MPP + -induced oxidative damage in animal models of PD.
